FDA Grants Accelerated Approval to New Breast Cancer Treatment, Etcamah

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer. This approval is for cases where an estrogen receptor-1 (ESR1) mutation is detected during aromatase inhibitor and CDK4/6 inhibitor therapy, expanding treatment options for patients whose tumors have developed acquired resistance mutations.